Addressing Student Needs By Offering Customized RSS Feeds

Rajiv Nariani
York University Libraries
rajivn@yorku.ca
TRY 2007
What are we covering

• RSS what is it – a quick introduction
• Set-up feeds in PubMed (medical database) on a specific topic
• See how our feeds can be customized using a web based application
Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study.


Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results


To evaluate possible benefits of cisplatin/gemcitabine and/or vinorelbine as induction chemotherapy prior to surgery, 205 patients with stage III NSCLC were assigned to receive cisplatin and gemcitabine alone or in combination with vinorelbine over 3 cycles, followed by surgery and consolidation chemotherapy. The 2-year overall survival rate was significantly higher in the cisplatin/gemcitabine and cisplatin/gemcitabine/ vinorelbine groups (79.6% and 65.1%, respectively) compared to the cisplatin/gemcitabine/vinorelbine group (45.2%). This suggests that the addition of vinorelbine to cisplatin/gemcitabine may not provide additional benefit in stage III NSCLC patients.
PubMed- Medical database by National Library of Medicine

- Go to www.pubmed.gov
- Do a search on a medical topic or condition
- Select your journals of interest from limits page – you can set other limits too!
- Let PubMed create RSS feed and you subscribe to the feed
- Now you can monitor the latest additions to PubMed without actually going to PubMed site
www.pubmed.gov

To get started, enter one or more search terms.
Search terms may be topics, authors or journals.

Set up an automated PubMed update in less than 5 minutes.

(1) Get a My NCBI account.  (2) Save your search.
(3) Your PubMed updates can be e-mailed directly to you.

Read the My NCBI Help material to explore other options, such as automated updates of other databases, setting search filters, and highlighting search terms.

PubMed is a service of the U.S. National Library of Medicine that includes over 17 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.
Adding the journals of your choice
Selecting more limits

RSS (Really Simple Syndication) is an XML-based format used to send new items or information to recipients who use RSS feed readers (available on the Web). PubMed RSS feeds include the latest biomedical articles with links back to PubMed citations.

- Automatic e-mailing of search updates is available using another service, My NCBI.
- Change options and click Create Feed.

Search for lung cancer AND ("Heart & lung : the journal of critical care" [Jour] OR "Lung" [Jour] OR "Lung cancer (Amsterdam, Netherlands)" [Jour]) Field: Title, Limits: Randomized Controlled Trial, Humans

Limit items if more than 15.

Right click on XML - copy and paste

If using firefox2 a regular click on the orange XML tab takes you to...


BACKGROUND: Chemotherapy has been widely accepted as standard for palliation in advanced non-small-cell lung cancer. Gemcitabine and docetaxel are active as single agents. Our previous experience indicates that single-agent therapy, if given sequentially, could be an alternative to doublet combination chemotherapy and that sequence and schedule matter. PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIIB-IV non-small-cell lung cancer were randomized to receive first-line 3-weekly gemcitabine or docetaxel. At progression, patients received second-line therapy with the other agent. Treatment was considered feasible if 30% of the evaluable patients had > or = 2 cycles of first-line and 2 cycles of second-line therapy and patient survival was > or = 7 months from the start of treatment. For efficacy, time to progression, overall survival, response, and quality of life were analyzed. RESULTS: Three hundred thirty patients received gemcitabine followed by docetaxel or docetaxel followed by gemcitabine. Treatment was feasible for 50 patients (38%) with gemcitabine followed by docetaxel and for 80 patients (49%) with docetaxel followed by gemcitabine; treatment favored docetaxel followed by gemcitabine (P = 0.03539). Median survival for gemcitabine followed by docetaxel and docetaxel followed by gemcitabine was 6.3 months and 8.6 months, and 1-year survival rate was 28% and 31%, respectively. Objective response rates were < or = 10% for both treatment strategies. Quality of life was significantly better in gemcitabine followed by docetaxel (P = 0.005). CONCLUSION: Single-agent gemcitabine and docetaxel are feasible as defined for both sequences but treatment favors docetaxel followed by gemcitabine. Thus, it is reasonable to state that single-agent therapy given sequentially might be a candidate for
Google Reader makes it easy to keep up with the latest content from a large number of sites, all on a single reading list.

Sign in to Google Reader with your Google Account

Email: rajvr2@gmail.com
Password: ************

Remember me on this computer.
Sign in

I cannot access my account

PubMed: lung cancer AND (*Lu...

You have subscribed to PubMed: lung cancer AND (*Lu...


You have already selected PubMed: lung cancer AND (*Lu...


Clin Lung Cancer. 2007 Jan-Feb;8(1):245-51


BACKGROUND: Chemotherapy has been widely accepted as standard for palliation in advanced non-small-cell lung cancer. Gemcitabine and docetaxel are active as single agents. Our previous experience indicates that single-agent therapy, if given sequentially, could be an alternative to doublet combination chemotherapy and that sequence and schedule matter.

METHODS: Chemotherapy-naive patients with stage III/IV non-small-cell lung cancer were randomized to receive first-line triple-agent gemcitabine or docetaxel. At progression, patients received second-line therapy with the other agent. Treatment was considered feasible if 30% of the evaluable patients had 

> or = 2 cycles of first-line and 2 cycles of second-line therapy and patient survival was 

> or = 7 months from the start of treatment. For efficacy, time to progression, overall survival, response, and quality of life were analyzed.

RESULTS: Three hundred thirty patients received
RSS feeds for journals

- RSS feeds for electronic journals from publishers
- RSS feeds from individual journals
- Tutorials on how to subscribe to e-journals on Steacie page
Displaying feed for your web page or blog
A feed can be in RSS, RDF, or Atom format. Outlines are in OPML format.

2 Customize your Widget
This is optional. If this widget looks good, you can go directly to the next step.

3 Save your Widget to a Web page
Type of Web Page
Generic Web Page

Install Options
Embedded Grazr Widget
Copy this text, and paste it into your HTML where you want your Grazr widget to appear.

```
```

Code goes on your web page
My customized Google page with PubMed results

Pasting code on your Library home page to display PubMed results
RSS feeds for Science & Engineering journals and databases from Steacie Library

1. Register for an account with bloglines (requires email & password)
2. Follow the instructions within the confirmation email
3. Select the "My feeds" tab > Click the "Add" link
4. Enter the URL of the RSS feed

**RSS Feeds from Publishers**

- [Cambridge Journals](http://www.cambridge.org/rss) (By Subject and By Title) Click on the journal of interest and subscribe to RSS feed
- [Informaworld](http://www.informaworld.com) is a one-stop site hosting journals, eBooks, abstract databases and reference works published and Informa Healthcare. Browse and subscribe to RSS journal feeds from this [link](http://www.informaworld.com/rss)
- [Sage Journals Online](http://www.sagepub.com/rss) (click on the journal of interest and subscribe to RSS feed)
- [IngentaConnect](http://www.ingentaconnect.com) (choose your subject area and subscribe to RSS feed of specific journals)
- [Blackwell Publishing Online Journals](http://www.blackwellpublishing.com/rss) (click on the journal of interest and subscribe to RSS feed)
- [Project MUSE @ RSS Feeds](http://www.muse.jhu.edu/rss) (right-click on the orange tab besides the journal of interest, select copy shortcut)

**RSS Feeds for Databases**

- Web of Science RSS Citation Alerts & RSS Alerts for Search Histories
- [EBSCO HOST](http://www.ebscohost.com) updated information [April 2007](http://www.ebscohost.com)
- [PubMed RSS Feeds](http://www.ncbi.nlm.nih.gov/pmc/rss) (help on setting up feeds)

---

**Some RSS Feeds for Science & Engineering Journals**

- [RSS Feeds for Science & Engineering Journals](http://library.ucsd.edu/) (University of California, San Diego)
- [Electronic Journals with RSS Feeds](http://www.ejc.edu/) (University of Nevada, Reno)
- American Chemical Society (ACS) Journals:
  - [Alphabetical List of Feeds](http://www.acs.org/)
  - [Feeds by Category](http://www.acs.org/)
  - [Patent Watch](http://www.acs.org/) (American Chemical Society)
- American Institute of Physics [RSS Feeds](http://www.aip.org/)

**Tutorials (video clips - best viewed in Internet Explorer browser)**

- [Subscribing to NewBooks@Steacie](http://library.ucsd.edu/) (in Firefox 2)
- [Subscribing to NewBooks@Steacie](http://library.ucsd.edu/) (in IE7)
- Subscribing to Web of Science RSS (using bloglines as feed reader)
Questions?
Rajiv Nariani
York University Libraries
rajin@yorku.ca